Premium
Junctophilins emerge as novel therapeutic targets
Author(s) -
Jiang Jinyong,
Tang Mingzhu,
Huang Zhen,
Chen Linxi
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.28405
Subject(s) - disease , pathophysiology , neuroscience , function (biology) , bioinformatics , diabetes mellitus , biology , medicine , pathology , microbiology and biotechnology , endocrinology
Junctophilins (JPs) emerge to play key role in human pathophysiology. This family includes four subtypes (JP1–4), which are differentially detected in excitable cells. Previous work demonstrated the knockout of JPs that seriously damage physiological functions in skeletal muscle, cardiac, and neurons. Here, we summarize latest papers on the essential function of JPs in some Ca 2+ ‐related diseases and neurological diseases, such as primary muscle disease, cardiomyopathies, Type 2 diabetes, gastrointestinal cancer, Huntington’s disease‐like 2, and Charcot‐Marie‐Tooth disease. Growing evidence suggests that targeting JPs might be a promising therapeutic approach to achieve better clinical efficacy in Ca 2+ ‐related diseases and neurological diseases.